Literature DB >> 1933908

Chronic nitrosamine ingestion in 1040 rodents: the effect of the choice of nitrosamine, the species studied, and the age of starting exposure.

R Gray1, R Peto, P Brantom, P Grasso.   

Abstract

In parallel with a larger experiment on 4080 rats fed 16 different concentrations of N-nitrosodiethylamine (NDEA) or N-nitrosodimethylamine (NDMA) from 6 weeks of age, a variety of smaller experiments on a total of 1040 rodents were undertaken and are the subject of the present report. Three separate subjects were addressed. Studies of 16 different concentrations of N-nitrosopyrrolidine and N-nitrosopiperidine given from age 6 weeks onwards to small groups of rats yielded dose-response relationships for the effects of N-nitrosopyrrolidine on liver tumors and for those of N-nitrosopiperidine on tumors of the liver and upper gastrointestinal tract that resembled those seen for NDMA and NDEA, respectively, except that N-nitrosopyrrolidine and N-nitrosopiperidine were less potent [the respective dose rates needed to halve the proportion of tumorless survivors after 2 years of treatment being approximately 0.4 (males) and 0.6 (females) mg/kg adult body weight/day for each agent]. Alternatively, it was estimated that the risks to rats from lifelong exposure to 1 microgram/kg adult body weight/day of each agent might be about 0.1%, and that the risks to rats from lower doses would be proportionately less. Studies of 16 different concentrations of NDEA on small groups of female mice and female hamsters yielded the types of dose response that would be expected for upper gastrointestinal tumors, liver cell tumors, and Kupffer cell tumors in mice (no other types of liver tumor being produced, in contrast with previous reports) and for tracheal and liver cell tumors in hamsters (no clear effect on upper gastrointestinal tumors being apparent in hamsters). The dose rates needed to halve the proportion of tumorless survivors after 2 years of treatment were approximately 0.3 mg/kg adult body weight/day, i.e., 5 times that for the same agent in rats. In part, however, this may be because treatment started at an older age in these species. Studies were undertaken of the effects on esophageal and liver tumorigenesis of starting the treatment of rats with NDEA at 3 or at 20 weeks of age instead of at 6 weeks of age (as in the main experiment). Earlier treatment resulted in slightly greater dosage rates, if dosage was measured in mg/kg/day, and hence in a correspondingly more rapid yield of esophageal tumors, but the effect was not large. By contrast, an earlier start to treatment resulted, after a fixed duration of treatment, in animals having a 3-fold higher incidence rate of liver tumors, while a later start resulted in a 2-fold decrease.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1933908

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  22 in total

1.  Quantitative implications of the approximate irrelevance of mammalian body size and lifespan to lifelong cancer risk.

Authors:  Richard Peto
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2015-07-19       Impact factor: 6.237

Review 2.  Evolution of research on the DNA adduct chemistry of N-nitrosopyrrolidine and related aldehydes.

Authors:  Stephen S Hecht; Pramod Upadhyaya; Mingyao Wang
Journal:  Chem Res Toxicol       Date:  2011-04-21       Impact factor: 3.739

3.  Gene expression of IQGAPs and Ras families in an experimental mouse model for hepatocellular carcinoma: a mechanistic study of cancer progression.

Authors:  Khairy M A Zoheir; Ahmed A Abd-Rabou; Gamaleldin I Harisa; Abdelkader E Ashour; Sheikh Fayaz Ahmad; Sabry M Attia; Saleh A Bakheet; Hala E Abdel-Hamied; Adel R Abd-Allah; Ashok Kumar
Journal:  Int J Clin Exp Pathol       Date:  2015-08-01

4.  Promotion of liver and lung tumorigenesis in DEN-treated cytoglobin-deficient mice.

Authors:  Le Thi Thanh Thuy; Takashi Morita; Kayo Yoshida; Kenichi Wakasa; Masashi Iizuka; Tomohiro Ogawa; Mami Mori; Yumiko Sekiya; Shinobu Momen; Hiroyuki Motoyama; Kazuo Ikeda; Katsutoshi Yoshizato; Norifumi Kawada
Journal:  Am J Pathol       Date:  2011-06-02       Impact factor: 4.307

5.  Mass spectrometric analysis of a cyclic 7,8-butanoguanine adduct of N-nitrosopyrrolidine: comparison to other N-nitrosopyrrolidine adducts in rat hepatic DNA.

Authors:  Ana Paula M Loureiro; Wenbing Zhang; Fekadu Kassie; Siyi Zhang; Peter W Villalta; Mingyao Wang; Stephen S Hecht
Journal:  Chem Res Toxicol       Date:  2009-10       Impact factor: 3.739

6.  Identification of adducts formed in the reaction of alpha-acetoxy-N-nitrosopyrrolidine with deoxyribonucleosides and DNA.

Authors:  Mingyao Wang; Yanbin Lao; Guang Cheng; Yongli Shi; Peter W Villalta; Stephen S Hecht
Journal:  Chem Res Toxicol       Date:  2007-03-30       Impact factor: 3.739

Review 7.  Experimental mouse models for hepatocellular carcinoma research.

Authors:  Femke Heindryckx; Isabelle Colle; Hans Van Vlierberghe
Journal:  Int J Exp Pathol       Date:  2009-08       Impact factor: 1.925

8.  Dietary polyphenols protect against N-nitrosamines and benzo(a)pyrene-induced DNA damage (strand breaks and oxidized purines/pyrimidines) in HepG2 human hepatoma cells.

Authors:  Maria Eugenia Delgado; Ana Isabel Haza; Núria Arranz; Almudena García; Paloma Morales
Journal:  Eur J Nutr       Date:  2008-10-30       Impact factor: 5.614

Review 9.  Liver carcinogenesis: rodent models of hepatocarcinoma and cholangiocarcinoma.

Authors:  Samuele De Minicis; Tatiana Kisseleva; Heather Francis; Gianluca Svegliati Baroni; Antonio Benedetti; David Brenner; Domenico Alvaro; Gianfranco Alpini; Marco Marzioni
Journal:  Dig Liver Dis       Date:  2012-11-22       Impact factor: 4.088

Review 10.  MicroRNAs in liver cancer: a model for investigating pathogenesis and novel therapeutic approaches.

Authors:  E Callegari; L Gramantieri; M Domenicali; L D'Abundo; S Sabbioni; M Negrini
Journal:  Cell Death Differ       Date:  2014-09-05       Impact factor: 15.828

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.